Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Therapeutics NV (NASDAQ: AGMB ) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn’s disease. • AgomAb Therapeutics stock is showing notable weakness. Why is AGMB stock dropping? The data demonstrated sustained disease control, lon